IMMX - Immix Short-Term Debt to Capital

Symbol and logo of brand Immix Biopharma (IMMX)

Immix Biopharma, Inc. (IMMX) is accelerating drug development through AI and automated synthesis, although medical personnel remain indispensable during trials. The company is implementing closed cultivation platforms to eliminate defects in drug production. This price action chart on GURU.Markets shows that the metric is 0.00. Meanwhile, the primary research centers are based in California, while vaccine production is delegated to external CDMO bio-factories.

Current Liabilities to Capital: immixbio.com (IMMX) for 07/04/2022 - 10/31/2026

Summary analytical data breakdowns for Immix (IMMX)

- stock value and consensus price forecast:
Price Chart Immix Biopharma, Inc.|IMMX - Broker Consensus Forecast
- market capitalization statistics:
Market Capitalization Immix Biopharma Inc.|IMMX - Real Price to Acquire Entire Company
- book capitalization information:
Net Assets per Single Share Immix Biopharma|IMMX - Total Stockholders' Equity|Market Value to Book Value Ratio immixbio.com|IMMX - Aggregate Company Assets
- issuer credit burden and liquidity indicators:
Debt to Equity Immix Biopharma, Inc.|IMMX - Long-Term Liabilities to Capital|Short-Term Debt to Capital Immix Biopharma, Inc.|IMMX - Company Total Indebtedness|Debt to Book Value Immix Biopharma Inc.|IMMX - Long-Term Debt|Company Current Liabilities Immix Biopharma|Quick Ratio immixbio.com
- company profitability and valuation multiples indicators:
IMMX - Net Financial Result
Initial company analysis:Immix Biopharma IMMX
Signature product of Immix

This ratio determines the company's dependence on obligations with a maturity of up to one year relative to its equity, signaling liquidity risks or aggressive growth financing. Analyzing the share of short-term loans in equity allows for an assessment of the stability of Immix Biopharma, Inc. (IMMX), whose expenditures on AI-driven drug synthesis automation must be balanced against costly clinical trials.

Competitors of Immix Biopharma, Inc. (IMMX)

Short-Term Debt to Equity ImmunityBio Corp (IBRX)|Immunocore Corp - Short-Term Debt to Capital Ratio|Short-Term Debt to Capital JANX (Janux Therapeutics)|RCUS - Short-Term Debt to Equity Ratio|ZYME - Short-Term Debt to Equity|Current Liabilities to Capital Tango Therapeutics Inc|Iovance (IOVA) - Short-Term Debt to Equity|IMTX (Immatics Biotechnologies) - Short-Term Debt to Equity|Short-Term Debt to Equity Xencor, Inc.|Current Liabilities to Capital compasstherapeutics.com CMPX|Short-Term Debt to Capital REPL|Lyell (LYEL) - Short-Term Indebtedness to Equity|Innate Pharma, S.A. - Short-Term Debt to Equity Ratio|Pyxis Oncology Inc. (PYXS) - Current Liabilities to Capital|CGEN: Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital IOBT (iobiotech.com)|STRO: Short-Term Debt to Capital|INKT - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Werewolf Therapeutics Inc.|Short-Term Debt to Equity Ratio alxoncology.com (ALXO)|Short-Term Debt to Equity Cue Biopharma (CUE)|Short-Term Debt to Equity Ratio pdsbiotech.com PDSB|Sonnet BioTherapeutics Holdings - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital MAIA Biotech MAIA|LIMN - Short-Term Debt to Equity|LVTX (LAVA Therapeutics N.V.) - Short-Term Debt to Capital Ratio|NextCure, Inc. (NXTC) - Short-Term Debt to Equity|Current Liabilities to Capital Leap Therapeutics (LPTX)|Short-Term Debt to Equity Ratio INTS|SNSE - Short-Term Indebtedness to Equity|Short-Term Debt to Equity Ratio TOVX (Synthetic Biologics)|Short-Term Loans to Capital Ratio GRTS|Short-Term Debt to Capital KA (Kineta, Inc.)|Ratio of Short-Term Indebtedness to Capital NEXI|Turnstone Biologics Corporation - Short-Term Debt to Capital|Current Liabilities to Capital Vaccinex Inc.|Harpoon Tx (HARP) - Short-Term Debt to Equity